An Israeli study has found that a vaccine originally developed to fight tuberculosis and commonly used to treat bladder cancer may also be effective in preventing Alzheimer’s disease, a chronic neurodegenerative illness that affects one in 10 adults over the of 65, and for which there is no cure at present. The research team, headed by Hervé Bercovier, Charles Greenblatt and Benjamin Klein at Hebrew University’s Department of Microbiology and Molecular Genetics, published their findings in PLOS ONE.  The team followed 1,371 bladder cancer patients, with an average age of 68, who were receiving treatment at Hadassah Medical Center. During follow-up visits, 65 cancer patients had developed Alzheimer's. The study found that the patients who had not received BCG as part of their treatment had a significantly higher risk of developing Alzheimer's than did BCG-treated patients.  KAN reporter Naomi Segal spoke with Prof. Bercovier about the study and its findings.